Small molecules in lung cancer targeted therapy: a two-decade bibliometric analysis and visualization (2005–2024)

Abstract

Purpose

In this study, a bibliometric analysis was performed to systematically characterize the research landscape of small molecule compounds for lung cancer (LC) treatment and identify emerging trends.

Methods

Data were extracted from the Web of Science Core Collection. The bibliometric software tools VOSviewer and CiteSpace were used to analyze publication trends, institutional collaboration networks, author contributions, and keyword co-occurrence patterns. Additionally, the patent portfolios of high-output authors and highly cited researchers were quantified.

Results

Annual publications have exhibited steady growth since 2011, with Asian countries (notably China) dominating output (80% of the top 10 institutions) and the USA leading in citation impact (52.79 average citations/publication). The patent analysis revealed a preponderant focus on drug synthesis methodologies, with high-output authors showing significant patent productivity. The co-occurrence analysis identified shifting research frontiers: early emphasis on epidermal growth factor receptor inhibitors transitioned post-2016 to emerging themes, including molecular docking, cancer metabolism, and migration.

Conclusion

This study highlights the translational emphasis of small molecule research in LC. However, significant geographical disparities exist, with Asian countries dominating publication output and the USA maintaining preeminence in citation impact. Future research should prioritize overcoming acquired resistance, leveraging natural product optimization, drug repurposing, advancing delivery systems, and exploring combination therapies.

Keywords

Lung cancer / Small molecule / Bibliometric analysis

References

[1] LeiterA, VeluswamyRR, WisniveskyJP. The global burden of lung cancer: current status and future trends. Nat Rev Clin Oncol, 2023, 209624-639.

[2] Ji Y, Zhang Y, Liu S, Li J, Jin Q, Wu J, et al. The epidemiological landscape of lung cancer: current status, temporal trend and future projections based on the latest estimates from GLOBOCAN 2022. Journal of the National Cancer Center. 2025. https://doi.org/10.1016/j.jncc.2025.01.003.

[3] LiY, YanB, HeS. Advances and challenges in the treatment of lung cancer. Biomed Pharmacother, 2023, 169. 115891

[4] Mitchell J, Lo K W. The Use of Small-Molecule Compounds for Cell Adhesion and Migration in Regenerative Medicine. Biomedicines. 2023;11(9). https://doi.org/10.3390/biomedicines11092507.

[5] YangNJ, HinnerMJ. Getting across the cell membrane: an overview for small molecules, peptides, and proteins. Methods Mol Biol, 2015, 1266: 29-53.

[6] PisaR, KapoorTM. Chemical strategies to overcome resistance against targeted anticancer therapeutics. Nat Chem Biol, 2020, 168817-825.

[7] ChenC. Searching for intellectual turning points: progressive knowledge domain visualization. Proc Natl Acad Sci U S A., 2004, 101 Suppl 1Suppl 15303-10.

[8] MosmannT. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods, 1983, 651–255-63.

[9] SungH, FerlayJ, SiegelRL, LaversanneM, SoerjomataramI, JemalA, et al. . Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin, 2021, 713209-249.

[10] LynchTJ, BellDW, SordellaR, GurubhagavatulaS, OkimotoRA, BranniganBW, et al. . Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med, 2004, 350212129-2139.

[11] PaezJG, JännePA, LeeJC, TracyS, GreulichH, GabrielS, et al. . EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy. Science, 2004, 30456761497-1500.

[12] KobayashiS, BoggonTJ, DayaramT, JännePA, KocherO, MeyersonM, et al. . EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med, 2005, 3528786-792.

[13] EngelmanJA, ZejnullahuK, MitsudomiT, SongY, HylandC, ParkJO, et al. . MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling. Science, 2007, 31658271039-1043.

[14] Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun M J. Cancer Statistics, 2007. CA: A Cancer Journal for Clinicians. 2007;57(1):43–66. https://doi.org/10.3322/canjclin.57.1.43.

[15] PaoW, MillerVA, PolitiKA, RielyGJ, SomwarR, ZakowskiMF, et al. . Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med, 2005, 23. e73

[16] SkehanP, StorengR, ScudieroD, MonksA, McMahonJ, VisticaD, et al. . New colorimetric cytotoxicity assay for anticancer-drug screening. J Natl Cancer Inst, 1990, 82131107-1112.

[17] HanahanD, WeinbergRA. Hallmarks of cancer: the next generation. Cell, 2011, 1445646-674.

[18] SinghS, SadhukhanS, SonawaneA. 20 years since the approval of first EGFR-TKI, gefitinib: Insight and foresight. Biochim Biophys Acta Rev Cancer, 2023, 18786. 188967

[19] SolcaF, DahlG, ZoephelA, BaderG, SandersonM, KleinC, et al. . Target binding properties and cellular activity of afatinib (BIBW 2992), an irreversible ErbB family blocker. J Pharmacol Exp Ther, 2012, 3432342-350.

[20] Singh S, Sadhukhan S, Sonawane A. 20 years since the approval of first EGFR-TKI, gefitinib: Insight and foresight. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer. 2023;1878(6):188967. https://doi.org/10.1016/j.bbcan.2023.188967.

[21] WangQ, YangS, WangK, SunSY. MET inhibitors for targeted therapy of EGFR TKI-resistant lung cancer. J Hematol Oncol, 2019, 12163.

[22] LuS, FangJ, LiX, CaoL, ZhouJ, GuoQ, et al. . Once-daily savolitinib in Chinese patients with pulmonary sarcomatoid carcinomas and other non-small-cell lung cancers harbouring MET exon 14 skipping alterations: a multicentre, single-arm, open-label, phase 2 study. Lancet Respir Med, 2021, 9101154-1164.

[23] PlanchardD, BesseB, GroenHJM, HashemiSMS, MazieresJ, KimTM, et al. . Phase 2 Study of Dabrafenib Plus Trametinib in Patients With BRAF V600E-Mutant Metastatic NSCLC: Updated 5-Year Survival Rates and Genomic Analysis. J Thorac Oncol, 2022, 171103-115.

[24] MilliganSA, BurkeP, ColemanDT, BigelowRL, SteffanJJ, CarrollJL, et al. . The green tea polyphenol EGCG potentiates the antiproliferative activity of c-Met and epidermal growth factor receptor inhibitors in non-small cell lung cancer cells. Clin Cancer Res, 2009, 15154885-4894.

[25] GaoZ, XuZ, HungMS, LinYC, WangT, GongM, et al. . Procaine and procainamide inhibit the Wnt canonical pathway by promoter demethylation of WIF-1 in lung cancer cells. Oncol Rep, 2009, 2261479-1484.

[26] AdeegbeDO, LiuY, LizottePH, KamiharaY, ArefAR, AlmonteC, et al. . Synergistic Immunostimulatory Effects and Therapeutic Benefit of Combined Histone Deacetylase and Bromodomain Inhibition in Non-Small Cell Lung Cancer. Cancer Discov, 2017, 78852-867.

[27] JiaD, AugertA, KimDW, EastwoodE, WuN, IbrahimAH, et al. . Crebbp Loss Drives Small Cell Lung Cancer and Increases Sensitivity to HDAC Inhibition. Cancer Discov, 2018, 8111422-1437.

[28] Del Bufalo D, Desideri M, De Luca T, Di Martile M, Gabellini C, Monica V, et al. Histone deacetylase inhibition synergistically enhances pemetrexed cytotoxicity through induction of apoptosis and autophagy in non-small cell lung cancer. Mol Cancer. 2014;13(230. https://doi.org/10.1186/1476-4598-13-230.

[29] AlsaedB, LinL, SonJ, LiJ, SmolanderJ, LopezT, et al. . Intratumor heterogeneity of EGFR expression mediates targeted therapy resistance and formation of drug tolerant microenvironment. Nat Commun, 2025, 16128.

[30] Guan X, Bao G, Liang J, Yao Y, Xiang Y, Zhong X. Evolution of small cell lung cancer tumor mutation: from molecular mechanisms to novel viewpoints. Seminars in Cancer Biology. 2022;86:346–55. https://doi.org/10.1016/j.semcancer.2022.03.015.

[31] PanZ, WangK, WangX, JiaZ, YangY, DuanY, et al. . Cholesterol promotes EGFR-TKIs resistance in NSCLC by inducing EGFR/Src/Erk/SP1 signaling-mediated ERRα re-expression. Mol Cancer, 2022, 21177.

[32] LiuQ, YuS, ZhaoW, QinS, ChuQ, WuK. EGFR-TKIs resistance via EGFR-independent signaling pathways. Mol Cancer, 2018, 17153.

[33] LiY, XieT, WangS, YangL, HaoX, WangY, et al. . Mechanism exploration and model construction for small cell transformation in EGFR-mutant lung adenocarcinomas. Signal Transduct Target Ther, 2024, 91261.

[34] Hanahan D, Weinberg Robert A. Hallmarks of Cancer: The Next Generation. Cell. 2011;144(5):646–74. https://doi.org/10.1016/j.cell.2011.02.013.

[35] LvY, ZhangW, ZhaoJ, SunB, QiY, JiH, et al. . SRSF1 inhibits autophagy through regulating Bcl-x splicing and interacting with PIK3C3 in lung cancer. Signal Transduct Target Ther, 2021, 61108.

[36] HanJH, KimYK, KimH, LeeJ, OhMJ, KimSB, et al. . Snail acetylation by autophagy-derived acetyl-coenzyme A promotes invasion and metastasis of KRAS-LKB1 co-mutated lung cancer cells. Cancer Commun (Lond), 2022, 428716-749.

[37] XuT, MaQ, LiY, YuQ, PanP, ZhengY, et al. . A small molecule inhibitor of the UBE2F-CRL5 axis induces apoptosis and radiosensitization in lung cancer. Signal Transduct Target Ther, 2022, 71354.

[38] WuZ, BezwadaD, CaiF, HarrisRC, KoB, SondhiV, et al. . Electron transport chain inhibition increases cellular dependence on purine transport and salvage. Cell Metab, 2024, 3671504-20.e9.

[39] HanM, BushongEA, SegawaM, TiardA, WongA, BradyMR, et al. . Spatial mapping of mitochondrial networks and bioenergetics in lung cancer. Nature, 2023, 6157953712-719.

[40] LiuQ, ZhangJ, GuoC, WangM, WangC, YanY, et al. . Proteogenomic characterization of small cell lung cancer identifies biological insights and subtype-specific therapeutic strategies. Cell, 2024, 1871184-203.e28.

[41] GilletteMA, SatpathyS, CaoS, DhanasekaranSM, VasaikarSV, KrugK, et al. . Proteogenomic Characterization Reveals Therapeutic Vulnerabilities in Lung Adenocarcinoma. Cell, 2020, 1821200-25.e35.

[42] YanY, SunD, HuJ, ChenY, SunL, YuH, et al. . Multi-omic profiling highlights factors associated with resistance to immuno-chemotherapy in non-small-cell lung cancer. Nat Genet, 2025, 571126-139.

[43] SunY, ChatterjeeS, LianX, TraylorZ, SattirajuSR, XiaoY, et al. . In vivo editing of lung stem cells for durable gene correction in mice. Science, 2024, 38467011196-1202.

[44] PlattRJ, ChenS, ZhouY, YimMJ, SwiechL, KemptonHR, et al. . CRISPR-Cas9 knockin mice for genome editing and cancer modeling. Cell, 2014, 1592440-455.

[45] LiHJ, QiuZB, WangMM, ZhangC, HongHZ, FuR, et al. . Radiomics-Based Support Vector Machine Distinguishes Molecular Events Driving the Progression of Lung Adenocarcinoma. J Thorac Oncol, 2025, 20152-64.

[46] De HerdtV. From bedside to bench and back. Eur J Neurol, 2021, 28113547.

[47] RudinCM, BrambillaE, Faivre-FinnC, SageJ. Small-cell lung cancer. Nat Rev Dis Primers, 2021, 713.

[48] Torres-DuránM, Curiel-GarcíaMT, Ruano-RavinaA, ProvencioM, Parente-LamelasI, Hernández-HernándezJ, et al. . Small-cell lung cancer in never-smokers. ESMO Open, 2021, 62. 100059

[49] SenT, TakahashiN, ChakrabortyS, TakebeN, NassarAH, KarimNA, et al. . Emerging advances in defining the molecular and therapeutic landscape of small-cell lung cancer. Nat Rev Clin Oncol, 2024, 218610-627.

[50] Tlemsani C, Takahashi N, Pongor L, Rajapakse V N, Tyagi M, Wen X, et al. Whole-exome sequencing reveals germline-mutated small cell lung cancer subtype with favorable response to DNA repair–targeted therapies. Science Translational Medicine. 2021;13(578):eabc7488. https://doi.org/10.1126/scitranslmed.abc7488.

[51] SchneiderJL, KurmiK, DaiY, DhimanI, JoshiS, GassawayBM, et al. . GUK1 activation is a metabolic liability in lung cancer. Cell, 2025.

[52] DoshiMB, LeeN, TseyangT, PonomarovaO, GoelHL, SpearsM, et al. . Disruption of sugar nucleotide clearance is a therapeutic vulnerability of cancer cells. Nature, 2023, 6237987625-632.

[53] WeiS, ZhaoQ, ZhengK, LiuP, ShaN, LiY, et al. . GFAT1-linked TAB1 glutamylation sustains p38 MAPK activation and promotes lung cancer cell survival under glucose starvation. Cell Discov, 2022, 8177.

[54] ZhaoH, WuL, YanG, ChenY, ZhouM, WuY, et al. . Inflammation and tumor progression: signaling pathways and targeted intervention. Signal Transduct Target Ther, 2021, 61263.

[55] ZhangH, AlmuqbilRM, AlhudaithiSS, SunbulFS, da RochaSRP. Pulmonary administration of a CSF-1R inhibitor alters the balance of tumor-associated macrophages and supports first-line chemotherapy in a lung cancer model. Int J Pharm, 2021, 598. 120350

[56] HuJ, Sánchez-RiveraFJ, WangZ, JohnsonGN, HoYJ, GaneshK, et al. . STING inhibits the reactivation of dormant metastasis in lung adenocarcinoma. Nature, 2023, 6167958806-813.

[57] Falchook G S, Liang Y, Harvey R D, Fu S, Weitao Y, Qin Y-r, et al. First-in-human phase 1 study of pimicotinib (ABSK021), a CSF-1R inhibitor, in patients with advanced solid tumors. Journal of Clinical Oncology. 2023;41(16_suppl):3100-. https://doi.org/10.1200/JCO.2023.41.16_suppl.3100.

[58] Gerber N K, Chmura S J, Luke J J, Shiao S L, Basho R, Iams W T, et al. A Phase 1 Study of TAK-676, a Novel STING Agonist, Plus Pembrolizumab Following Radiation Therapy in Patients with Advanced Non–Small-Cell Lung Cancer (NSCLC), Triple-Negative Breast Cancer (TNBC), or Squamous-Cell Carcinoma of the Head and Neck (SCCHN). International Journal of Radiation Oncology*Biology*Physics. 2022;114(3, Supplement):e40. https://doi.org/10.1016/j.ijrobp.2022.07.762.

[59] BessedeA, PeyraudF, Le MoulecS, CousinS, CabartM, ChomyF, et al. . Upregulation of Indoleamine 2,3-Dioxygenase 1 in Tumor Cells and Tertiary Lymphoid Structures is a Hallmark of Inflamed Non-Small Cell Lung Cancer. Clin Cancer Res, 2023, 29234883-4893.

[60] GuX, ZhuY, SuJ, WangS, SuX, DingX, et al. . Lactate-induced activation of tumor-associated fibroblasts and IL-8-mediated macrophage recruitment promote lung cancer progression. Redox Biol, 2024, 74. 103209

[61] UchiboriK, InaseN, ArakiM, KamadaM, SatoS, OkunoY, et al. . Brigatinib combined with anti-EGFR antibody overcomes osimertinib resistance in EGFR-mutated non-small-cell lung cancer. Nat Commun, 2017, 8114768.

[62] DuP, HuT, AnZ, LiP, LiuL. In vitro and in vivo synergistic efficacy of ceritinib combined with programmed cell death ligand-1 inhibitor in anaplastic lymphoma kinase-rearranged non-small-cell lung cancer. Cancer Sci, 2020, 11161887-1898.

[63] WangC, WangM, YuB. 1169TiP Penpulimab-based combination neoadjuvant/adjuvant therapy for patients with resectable locally advanced non-small cell lung cancer: A phase II clinical study (ALTER-L043). Ann Oncol, 2021, 32: S938.

[64] Zhou X, Wang X, Sun Q, Zhang W, Liu C, Ma W, et al. Natural compounds: A new perspective on targeting polarization and infiltration of tumor-associated macrophages in lung cancer. Biomedicine & Pharmacotherapy. 2022;151:113096. https://doi.org/10.1016/j.biopha.2022.113096.

[65] Alsharairi N A. Quercetin Derivatives as Potential Therapeutic Agents: An Updated Perspective on the Treatment of Nicotine-Induced Non-Small Cell Lung Cancer. Int J Mol Sci. 2023;24(20):https://doi.org/10.3390/ijms242015208.

[66] LiJ, ZhangD, WangS, YuP, SunJ, ZhangY, et al. . Baicalein induces apoptosis by inhibiting the glutamine-mTOR metabolic pathway in lung cancer. J Adv Res, 2025, 68: 341-357.

[67] Chen T, Zhang P, Cong X F, Wang Y Y, Li S, Wang H, et al. Synergistic antitumor activity of baicalein combined with almonertinib in almonertinib-resistant non-small cell lung cancer cells through the reactive oxygen species-mediated PI3K/Akt pathway. Front Pharmacol. 2024;15(1405521. https://doi.org/10.3389/fphar.2024.1405521.

[68] Domingo-FernándezD, GadiyaY, PretoAJ, KrettlerCA, MubeenS, AllenA, et al. . Natural Products Have Increased Rates of Clinical Trial Success throughout the Drug Development Process. J Nat Prod, 2024, 8771844-1851.

[69] SuvileshKN, ManjunathY, NussbaumYI, GadelkarimM, RajuM, SrivastavaA, et al. . Targeting AKR1B10 by Drug Repurposing with Epalrestat Overcomes Chemoresistance in Non-Small Cell Lung Cancer Patient-Derived Tumor Organoids. Clin Cancer Res, 2024, 30173855-3867.

[70] MacayaI, RomanM, WelchC, Entrialgo-CadiernoR, SalmonM, SantosA, et al. . Signature-driven repurposing of Midostaurin for combination with MEK1/2 and KRASG12C inhibitors in lung cancer. Nat Commun, 2023, 1416332.

[71] ZhengX, WuY, ZuoH, ChenW, WangK. Metal Nanoparticles as Novel Agents for Lung Cancer Diagnosis and Therapy. Small, 2023, 1918. e2206624

[72] SpigelDR, DowlatiA, ChenY, NavarroA, YangJC, StojanovicG, et al. . RESILIENT Part 2: A Randomized, Open-Label Phase III Study of Liposomal Irinotecan Versus Topotecan in Adults With Relapsed Small Cell Lung Cancer. J Clin Oncol, 2024, 42192317-2326.

[73] WengW, MengT, ZhaoQ, ShenY, FuG, ShiJ, et al. . Antibody-Exatecan Conjugates with a Novel Self-immolative Moiety Overcome Resistance in Colon and Lung Cancer. Cancer Discov, 2023, 134950-973.

[74] PassaroA, JännePA, PetersS. Antibody-Drug Conjugates in Lung Cancer: Recent Advances and Implementing Strategies. J Clin Oncol, 2023, 41213747-3761.

[75] OwenDH, GiffinMJ, BailisJM, SmitMD, CarboneDP, HeK. DLL3: an emerging target in small cell lung cancer. J Hematol Oncol, 2019, 12161.

[76] LinS, ZhangY, YaoJ, YangJ, QiuY, ZhuZ, et al. . DB-1314, a novel DLL3-targeting ADC with DNA topoisomerase I inhibitor, exhibits promising safety profile and therapeutic efficacy in preclinical small cell lung cancer models. J Transl Med, 2024, 221766.

[77] JiangY, HuangW, SunX, YangX, WuY, ShiJ, et al. . DTX-P7, a peptide-drug conjugate, is highly effective for non-small cell lung cancer. J Hematol Oncol, 2022, 15173.

[78] Bazylevich A, Miller A, Tkachenko I, Merlani M, Patsenker L, Gellerman G, et al. Novel Cyclic Peptide-Drug Conjugate P6-SN38 Toward Targeted Treatment of EGFR Overexpressed Non-Small Cell Lung Cancer. Pharmaceutics. 2024;16(12). https://doi.org/10.3390/pharmaceutics16121613.

[79] Gou S, Wang G, Zou Y, Geng W, He T, Qin Z, et al. Non-Pore Dependent and MMP-9 Responsive Gelatin/Silk Fibroin Composite Microparticles as Universal Delivery Platform for Inhaled Treatment of Lung Cancer. Advanced Materials. 2023;35(42):2303718. https://doi.org/10.1002/adma.202303718.

Funding

Shanghai Youth Talent Program of Eastern Talent Plan

RIGHTS & PERMISSIONS

The Author(s)